1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Hemmi, H. Yoshida, T. Kumazaki, T. Nemoto, N. Hasegawa, J. Nishioka, F. Kyogoku, Y. Yokosawa, H. Kobayashi, Y. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 41 10657 10664 10.1021/bi026035o 12186551 Solution structure of ascidian trypsin inhibitor determined by nuclear magnetic resonance spectroscopy. 2002 10.2210/pdb1iw4/pdb pdb_00001iw4 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 6084.985 trypsin inhibitor 1 nat polymer no no AHMDCTEFNPLCRCNKMLGDLICAVIGDAKEEHRNMCALCCEHPGGFEYSNGPCE AHMDCTEFNPLCRCNKMLGDLICAVIGDAKEEHRNMCALCCEHPGGFEYSNGPCE A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Halocynthia sample 7729 Halocynthia roretzi database_2 pdbx_database_status pdbx_nmr_software pdbx_nmr_spectrometer pdbx_struct_assembly pdbx_struct_oper_list database_2 pdbx_database_status repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations Other Database references Other 1 0 2002-08-28 1 1 2008-04-27 1 2 2011-07-13 1 3 2020-02-26 1 4 2023-06-14 _pdbx_database_status.status_code_cs _pdbx_nmr_software.name _pdbx_nmr_spectrometer.model _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data 5348 is chemical shifts of this protein PDBJ Y PDBJ 2002-04-19 REL REL REL REL The structure was determined using standard 2D homonuclear techniques. structures with the lowest energy 100 20 NOESY DQF-COSY E-COSY TOCSY TOCSY 3.7 ambient 303 K 3.7 ambient 303 K simulated annealing 1 lowest energy 1.5-2.0mM ascidian trypsin inhibitor; 90% H2O, 10% D2O 90% H2O/10% D2O 1.5-2.0mM ascidian trypsin inhibitor; D2O D2O Bruker collection XwinNMR 2.6 Delaglio processing NMRPipe 2.1 Garrett data analysis NMRPIPP 4.3.2 Brunger refinement CNS 1.0 500 Bruker AVANCE 600 Bruker DRX 750 Bruker DMX 600 JEOL A ALA 1 n 1 ALA 1 A HIS 2 n 2 HIS 2 A MET 3 n 3 MET 3 A ASP 4 n 4 ASP 4 A CYS 5 n 5 CYS 5 A THR 6 n 6 THR 6 A GLU 7 n 7 GLU 7 A PHE 8 n 8 PHE 8 A ASN 9 n 9 ASN 9 A PRO 10 n 10 PRO 10 A LEU 11 n 11 LEU 11 A CYS 12 n 12 CYS 12 A ARG 13 n 13 ARG 13 A CYS 14 n 14 CYS 14 A ASN 15 n 15 ASN 15 A LYS 16 n 16 LYS 16 A MET 17 n 17 MET 17 A LEU 18 n 18 LEU 18 A GLY 19 n 19 GLY 19 A ASP 20 n 20 ASP 20 A LEU 21 n 21 LEU 21 A ILE 22 n 22 ILE 22 A CYS 23 n 23 CYS 23 A ALA 24 n 24 ALA 24 A VAL 25 n 25 VAL 25 A ILE 26 n 26 ILE 26 A GLY 27 n 27 GLY 27 A ASP 28 n 28 ASP 28 A ALA 29 n 29 ALA 29 A LYS 30 n 30 LYS 30 A GLU 31 n 31 GLU 31 A GLU 32 n 32 GLU 32 A HIS 33 n 33 HIS 33 A ARG 34 n 34 ARG 34 A ASN 35 n 35 ASN 35 A MET 36 n 36 MET 36 A CYS 37 n 37 CYS 37 A ALA 38 n 38 ALA 38 A LEU 39 n 39 LEU 39 A CYS 40 n 40 CYS 40 A CYS 41 n 41 CYS 41 A GLU 42 n 42 GLU 42 A HIS 43 n 43 HIS 43 A PRO 44 n 44 PRO 44 A GLY 45 n 45 GLY 45 A GLY 46 n 46 GLY 46 A PHE 47 n 47 PHE 47 A GLU 48 n 48 GLU 48 A TYR 49 n 49 TYR 49 A SER 50 n 50 SER 50 A ASN 51 n 51 ASN 51 A GLY 52 n 52 GLY 52 A PRO 53 n 53 PRO 53 A CYS 54 n 54 CYS 54 A GLU 55 n 55 GLU 55 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 A O GLU 31 A O GLU 31 A N ALA 24 A N ALA 24 A N VAL 25 A N VAL 25 A O GLU 48 A O GLU 48 1 A A O N ASN MET 15 17 2.00 1 A A O N LEU ARG 11 13 2.01 2 A A O N ASN MET 15 17 2.03 2 A A O N LEU ARG 11 13 2.11 3 A A O N ASN MET 15 17 2.01 3 A A O N LEU ARG 11 13 2.11 4 A A O H LEU ARG 11 13 1.49 4 A A O N LEU ARG 11 13 2.03 5 A A O H ASN MET 15 17 1.28 5 A A O N ASN MET 15 17 2.15 5 A A O N LEU ARG 11 13 2.18 6 A A O H LEU GLY 21 52 1.46 6 A A O H LYS LEU 16 18 1.48 6 A A O N ASN MET 15 17 2.05 6 A A O N LEU ARG 11 13 2.06 7 A A O N ASN MET 15 17 2.02 7 A A O N LEU ARG 11 13 2.03 8 A A O H LYS LEU 16 18 1.58 8 A A O N ASN MET 15 17 2.03 8 A A O N LEU ARG 11 13 2.05 9 A A O H LYS LEU 16 18 1.50 9 A A O N ASN MET 15 17 2.05 9 A A O N LEU ARG 11 13 2.14 10 A A O N ASN MET 15 17 2.03 11 A A O N LEU ARG 11 13 2.17 12 A A O H ASN MET 15 17 1.34 12 A A O N LEU ARG 11 13 2.07 13 A A O N ASN MET 15 17 2.03 13 A A O N LEU ARG 11 13 2.13 14 A A O N LEU ARG 11 13 2.11 15 A A O H ASN MET 15 17 1.42 15 A A O N ASN MET 15 17 2.04 15 A A O N LEU ARG 11 13 2.13 16 A A O N ASN MET 15 17 2.03 16 A A O N LEU ARG 11 13 2.05 17 A A O N LEU ARG 11 13 2.01 18 A A O N ASN MET 15 17 2.04 19 A A O N ASN MET 15 17 2.03 19 A A O N LEU ARG 11 13 2.03 20 A A O H LYS LEU 16 18 1.53 20 A A O N ASN MET 15 17 2.04 20 A A O N LEU ARG 11 13 2.17 20 A A O N LYS LEU 16 18 2.19 1 A HIS 2 -69.58 84.64 1 A GLU 7 -42.07 78.05 1 A PHE 8 -160.68 -147.67 1 A ASN 9 -69.11 -71.28 1 A LEU 11 -47.84 171.42 1 A CYS 12 -28.00 62.98 1 A ARG 13 -92.38 41.48 1 A LYS 16 -20.44 57.49 1 A MET 17 -65.09 78.58 1 A LEU 18 -170.87 59.39 1 A ASP 20 -54.43 178.25 1 A LEU 21 -170.35 66.11 1 A ASP 28 -154.08 24.22 2 A HIS 2 -114.91 52.39 2 A THR 6 -61.16 -116.85 2 A GLU 7 179.37 26.38 2 A PRO 10 -67.06 87.58 2 A LEU 11 -47.81 -167.97 2 A CYS 12 -17.79 60.71 2 A ARG 13 -98.22 42.85 2 A LYS 16 -19.45 58.21 2 A LEU 18 -162.65 59.18 2 A ASP 28 -152.47 23.59 2 A PHE 47 -61.92 -122.87 2 A CYS 54 -164.16 -73.03 3 A HIS 2 -69.83 72.48 3 A MET 3 -170.87 103.49 3 A ASP 4 179.54 30.79 3 A THR 6 -62.14 -124.33 3 A GLU 7 179.13 24.56 3 A PRO 10 -66.92 71.85 3 A LEU 11 -54.78 -170.62 3 A CYS 12 -17.97 65.85 3 A ARG 13 -80.37 30.69 3 A ASN 15 -160.71 -53.40 3 A LYS 16 -19.71 57.75 3 A LEU 18 -171.18 63.25 3 A ASP 28 -154.91 24.28 3 A PHE 47 -48.82 167.21 3 A CYS 54 177.06 -36.66 4 A MET 3 -171.85 -62.46 4 A ASP 4 -23.70 118.10 4 A CYS 5 -160.67 -159.70 4 A GLU 7 -34.63 89.81 4 A PHE 8 -160.02 -155.80 4 A LEU 11 -57.03 179.59 4 A CYS 12 -37.18 63.18 4 A ARG 13 -91.88 41.53 4 A ASN 15 -104.09 -73.45 4 A MET 17 -19.75 142.15 4 A LEU 18 -68.82 69.35 4 A ASP 28 -150.82 22.38 4 A PHE 47 -52.73 -125.83 4 A CYS 54 -168.61 -59.28 5 A ASP 4 179.90 76.63 5 A THR 6 -52.88 -105.11 5 A GLU 7 178.29 -22.31 5 A PRO 10 -67.77 70.92 5 A LEU 11 -51.21 -160.24 5 A CYS 12 -16.03 69.58 5 A ARG 13 -97.06 31.58 5 A LYS 16 -51.40 55.76 5 A MET 17 -44.42 89.48 5 A LEU 18 -170.43 52.29 5 A ASP 20 -69.79 -179.53 5 A ASP 28 -154.43 24.09 5 A PRO 44 -69.39 90.27 5 A PHE 47 -62.83 -149.45 5 A PRO 53 -65.47 97.43 6 A MET 3 -171.27 -78.97 6 A ASP 4 -47.99 88.85 6 A GLU 7 -19.72 82.85 6 A PHE 8 -160.85 -151.62 6 A LEU 11 -52.31 176.22 6 A CYS 12 -19.47 62.60 6 A ARG 13 -86.00 34.99 6 A LYS 16 -19.31 61.69 6 A MET 17 -61.37 55.55 6 A LEU 18 -171.15 58.32 6 A ASP 20 -49.77 -178.53 6 A ASP 28 -164.85 28.57 6 A PHE 47 -60.97 -118.42 7 A HIS 2 -106.25 57.60 7 A ASP 4 179.67 61.72 7 A GLU 7 -18.80 80.68 7 A PHE 8 -160.35 -144.54 7 A LEU 11 -66.82 -178.58 7 A CYS 12 -18.30 60.41 7 A LYS 16 -19.79 58.71 7 A MET 17 -61.94 74.14 7 A LEU 18 -171.11 59.75 7 A ASP 20 -63.91 -177.10 7 A ASP 28 -154.83 23.89 7 A ARG 34 -111.39 -71.13 7 A PRO 44 -57.55 71.19 7 A CYS 54 -157.01 -44.91 8 A HIS 2 -129.06 -151.83 8 A MET 3 -68.47 -161.47 8 A ASP 4 -34.20 93.78 8 A GLU 7 -25.53 86.14 8 A PHE 8 -160.66 -157.30 8 A CYS 12 -19.82 59.58 8 A ARG 13 -81.47 32.47 8 A LYS 16 -19.41 60.54 8 A MET 17 -49.13 66.67 8 A LEU 18 -171.19 52.31 8 A ILE 26 -159.96 88.65 8 A ASP 28 -146.94 21.05 8 A PHE 47 -51.52 175.16 8 A CYS 54 -167.70 -41.73 9 A HIS 2 -140.93 -152.18 9 A MET 3 -67.12 71.69 9 A CYS 5 -133.98 -140.19 9 A GLU 7 -19.17 75.59 9 A PHE 8 -160.71 -153.23 9 A CYS 12 -18.78 67.03 9 A ARG 13 -94.04 38.30 9 A LYS 16 -19.28 61.54 9 A MET 17 -62.80 54.36 9 A LEU 18 -170.88 65.80 9 A ASP 20 -49.36 179.98 9 A ASP 28 -154.15 24.90 9 A PRO 44 -58.85 78.99 9 A PHE 47 -52.48 -175.55 10 A HIS 2 -69.62 65.68 10 A MET 3 -117.70 -88.98 10 A ASP 4 -42.22 164.36 10 A CYS 5 -161.07 -167.65 10 A THR 6 -44.16 -88.06 10 A GLU 7 178.83 -28.03 10 A PHE 8 -152.08 -152.03 10 A LEU 11 -48.63 -163.15 10 A CYS 12 -16.78 69.73 10 A ARG 13 -97.44 31.40 10 A ASN 15 -170.18 -52.00 10 A LYS 16 -19.53 56.85 10 A MET 17 -67.59 77.20 10 A LEU 18 -170.67 59.77 10 A ASP 20 -57.41 176.71 10 A LEU 21 -156.29 84.52 10 A ASP 28 -158.53 26.73 10 A PHE 47 -48.76 161.33 10 A CYS 54 -130.10 -52.75 11 A HIS 2 -124.30 -154.29 11 A MET 3 -67.11 -166.75 11 A CYS 5 -79.98 -134.61 11 A THR 6 -64.15 -72.03 11 A GLU 7 179.26 -19.89 11 A PHE 8 -156.10 -156.88 11 A PRO 10 -64.71 83.25 11 A LEU 11 -43.85 -167.51 11 A CYS 12 -17.26 64.27 11 A ASN 15 -170.54 -70.14 11 A LYS 16 -70.28 34.12 11 A MET 17 -43.64 151.80 11 A LEU 18 -69.60 62.68 11 A ASP 28 -157.01 25.04 11 A CYS 54 174.99 -36.87 12 A HIS 2 -95.42 32.38 12 A MET 3 -159.98 -110.04 12 A GLU 7 -19.97 81.12 12 A PHE 8 -160.75 -152.22 12 A LEU 11 -52.54 174.46 12 A CYS 12 -19.36 64.06 12 A ARG 13 -92.58 42.20 12 A LYS 16 -61.27 52.28 12 A MET 17 -34.12 119.68 12 A ASP 28 -155.86 22.73 12 A PRO 44 -50.72 -177.27 12 A PHE 47 -38.18 -111.10 12 A CYS 54 -169.84 -77.33 13 A ASP 4 -159.52 77.62 13 A THR 6 -60.87 -119.47 13 A GLU 7 179.05 26.24 13 A LEU 11 -54.01 -169.30 13 A CYS 12 -17.69 66.35 13 A ARG 13 -100.03 42.99 13 A LYS 16 -22.67 60.73 13 A MET 17 -64.65 65.47 13 A LEU 18 -171.35 107.78 13 A ASP 20 -59.20 175.85 13 A ASP 28 -159.73 32.55 13 A PRO 44 -66.42 84.41 13 A PHE 47 -54.13 -176.27 13 A CYS 54 -115.18 -90.81 14 A MET 3 -172.98 -54.43 14 A ASP 4 -47.46 106.38 14 A CYS 5 -160.27 -162.19 14 A GLU 7 -19.26 84.43 14 A PHE 8 -160.46 -160.71 14 A LEU 11 -55.61 175.20 14 A CYS 12 -19.80 67.62 14 A ARG 13 -86.60 40.67 14 A CYS 14 -129.36 -167.71 14 A ASN 15 -110.25 -146.58 14 A MET 17 -52.45 -171.46 14 A LEU 18 -68.89 68.74 14 A ASP 28 -151.30 23.50 14 A ARG 34 -81.70 -76.58 14 A CYS 54 -178.43 -63.97 15 A ASP 4 179.90 72.87 15 A THR 6 -59.65 -107.75 15 A GLU 7 179.47 23.31 15 A PRO 10 -64.59 76.88 15 A LEU 11 -50.85 -169.15 15 A CYS 12 -17.78 65.32 15 A ARG 13 -86.33 36.15 15 A LYS 16 -37.21 59.89 15 A MET 17 -53.18 81.19 15 A LEU 18 -170.89 51.86 15 A ASP 20 -51.73 -177.12 15 A ASP 28 -155.26 25.57 15 A PRO 44 -72.78 49.95 15 A PHE 47 -63.53 -124.10 15 A GLU 48 -160.35 116.44 15 A CYS 54 -129.18 -56.70 16 A MET 3 -170.00 -92.18 16 A ASP 4 -43.77 106.52 16 A GLU 7 -40.88 81.21 16 A PHE 8 -160.60 -150.55 16 A LEU 11 -59.62 171.94 16 A CYS 12 -19.41 63.42 16 A LYS 16 -18.70 58.20 16 A MET 17 -64.46 82.62 16 A ASP 28 -164.45 28.24 16 A ARG 34 -96.58 -61.81 16 A PRO 44 -56.27 84.77 16 A PHE 47 -19.68 -107.33 16 A CYS 54 -153.17 -34.28 17 A MET 3 -136.33 -137.83 17 A ASP 4 -29.54 80.57 17 A CYS 5 -161.53 -162.91 17 A GLU 7 -86.30 49.55 17 A PHE 8 -160.20 -151.32 17 A CYS 12 -17.78 62.39 17 A CYS 14 -170.38 108.54 17 A ASN 15 -73.35 -96.06 17 A MET 17 -52.09 176.68 17 A LEU 18 -69.07 71.54 17 A ASP 28 -154.52 24.04 17 A ARG 34 -98.20 -66.95 17 A PHE 47 -61.67 -119.14 17 A CYS 54 -161.57 -67.30 18 A MET 3 -171.07 118.77 18 A ASP 4 -155.95 51.88 18 A GLU 7 177.99 -17.90 18 A PHE 8 -156.20 -148.89 18 A PRO 10 -60.17 78.25 18 A LEU 11 -52.80 -162.82 18 A CYS 12 -17.14 66.92 18 A LYS 16 -19.35 58.86 18 A MET 17 -65.15 66.17 18 A LEU 18 -170.38 52.40 18 A ASP 20 -62.68 -179.63 18 A ASP 28 -150.25 20.48 18 A PRO 44 -54.11 85.91 18 A PHE 47 -29.19 -110.69 18 A SER 50 -151.94 79.90 18 A CYS 54 -176.63 -68.27 19 A HIS 2 -130.64 -153.12 19 A MET 3 -68.70 -159.18 19 A ASP 4 -19.63 130.74 19 A THR 6 -35.49 -30.52 19 A GLU 7 -18.58 85.01 19 A PHE 8 -160.32 -141.61 19 A ASN 9 -69.34 -74.56 19 A LEU 11 -40.35 169.05 19 A CYS 12 -18.81 60.41 19 A ARG 13 -91.95 39.66 19 A LYS 16 -19.40 58.49 19 A LEU 18 -170.44 65.88 19 A ASP 20 -53.63 178.62 19 A ASP 28 -152.08 23.97 19 A PHE 47 -50.96 174.73 19 A CYS 54 -151.80 -47.58 20 A MET 3 -170.51 -36.88 20 A CYS 5 -150.34 -139.44 20 A THR 6 -66.10 -70.57 20 A GLU 7 179.64 -28.87 20 A PHE 8 -161.04 -141.26 20 A PRO 10 -66.66 72.39 20 A LEU 11 -46.27 -158.27 20 A CYS 12 -17.33 65.73 20 A ARG 13 -93.77 32.07 20 A LYS 16 -19.49 61.49 20 A MET 17 -45.48 63.88 20 A LEU 18 -171.19 57.50 20 A ASP 28 -153.84 22.17 20 A PRO 44 -53.11 86.93 20 A PHE 47 -56.55 -114.67 20 A SER 50 -155.62 82.30 20 A CYS 54 -133.44 -68.19 Solution structure of ascidian trypsin inhibitor 1 N N A ASN 35 A ASN 35 HELX_P A HIS 43 A HIS 43 1 1 9 disulf 2.028 A CYS 5 A SG CYS 5 1_555 A CYS 40 A SG CYS 40 1_555 disulf 2.024 A CYS 12 A SG CYS 12 1_555 A CYS 41 A SG CYS 41 1_555 disulf 2.032 A CYS 14 A SG CYS 14 1_555 A CYS 37 A SG CYS 37 1_555 disulf 2.030 A CYS 23 A SG CYS 23 1_555 A CYS 54 A SG CYS 54 1_555 PROTEIN BINDING solution structure, ascidian, trypsin inhibitor, cystine-stabilized alpha-helical motif, disulfide bond, Kazal-type inhibitor, PROTEIN BINDING ITRP_HALRO UNP 1 1 P16589 AHMDCTEFNPLCRCNKMLGDLICAVIGDAKEEHRNMCALCCEHPGGFEYSNGPCE 1 55 1IW4 1 55 P16589 A 1 1 55 3 anti-parallel anti-parallel A GLU 31 A GLU 31 A HIS 33 A HIS 33 A ILE 22 A ILE 22 A VAL 25 A VAL 25 A GLU 48 A GLU 48 A TYR 49 A TYR 49